CLINICAL TRIALS PROFILE FOR SODIUM SUCCINATE

All Clinical Trials for Sodium Succinate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00290602 ↗	Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome	Completed	National Cancer Center, Korea	Phase 2	2004-02-01	The purpose of this study is to determine whether the 2mg/kg administration of corticosteroids, in the form of methylprednisolone sodium succinate, in early phase acute respiratory distress syndrome after thoracic surgery, will reduce the postoperative mortality.
NCT00295269 ↗	Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress Syndrome	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1997-03-01	The purpose of this study is to assess innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS.
NCT00329355 ↗	Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)	Completed	GlaxoSmithKline	Phase 3	2006-05-01	This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00329459 ↗	Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea	Completed	GlaxoSmithKline	Phase 3	2006-05-01	This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine.
NCT00382993 ↗	A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)	Completed	GlaxoSmithKline	Phase 3	2006-12-01	This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2]
NCT00383162 ↗	A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)	Completed	GlaxoSmithKline	Phase 3	2006-11-01	This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 1 of 2]

Clinical Trial Conditions for Sodium Succinate

Condition Name

Condition Name for Sodium Succinate
Intervention	Trials
Migraine Disorders	7
Migraine With or Without Aura	2
Lung Diseases	2
Acute Respiratory Distress Syndrome	2

Condition MeSH

Condition MeSH for Sodium Succinate
Intervention	Trials
Migraine Disorders	11
Leukemia, Lymphoid	5
Leukemia	5
Precursor Cell Lymphoblastic Leukemia-Lymphoma	5

Clinical Trial Locations for Sodium Succinate

Trials by Country

Trials by Country for Sodium Succinate
Location	Trials
United States	303
Canada	15
Australia	8
China	4
Puerto Rico	3

Trials by US State

Trials by US State for Sodium Succinate
Location	Trials
Tennessee	11
North Carolina	11
California	10
Washington	10
Texas	10

Clinical Trial Progress for Sodium Succinate

Clinical Trial Phase

Clinical Trial Phase for Sodium Succinate
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	14
Phase 2	7

Clinical Trial Status

Clinical Trial Status for Sodium Succinate
Clinical Trial Phase	Trials
Completed	23
Recruiting	5
Not yet recruiting	3

Clinical Trial Sponsors for Sodium Succinate

Sponsor Name

Sponsor Name for Sodium Succinate
Sponsor	Trials
GlaxoSmithKline	9
National Cancer Institute (NCI)	5
National Heart, Lung, and Blood Institute (NHLBI)	2

Sponsor Type

Sponsor Type for Sodium Succinate
Sponsor	Trials
Other	39
Industry	13
NIH	8

Sodium Succinate: Clinical Trials, Market Analysis, and Projections

Introduction

Sodium succinate, a derivative of succinic acid, is a compound with diverse applications in pharmaceuticals, food, and other industries. This article will delve into the current state of clinical trials, market analysis, and future projections for sodium succinate.

Clinical Trials and Medical Applications

While there is limited specific information on ongoing clinical trials exclusively for sodium succinate, it is often used as an intermediate or component in various pharmaceutical formulations.

Role in Pharmaceutical Formulations

Sodium succinate can be used as a buffering agent or in the synthesis of other pharmaceutical compounds. For instance, in the context of cancer treatment, sodium succinate might be involved in the formulation of drugs like those used in the AALL1821 study, although it is not the primary focus of such trials[1].

Future Potential

Given its chemical properties, sodium succinate could be explored in future clinical trials for its potential therapeutic benefits, such as its antioxidant properties or its role in energy metabolism. However, as of now, there are no prominent clinical trials specifically focused on sodium succinate.

Market Analysis

Global Market Size and Growth

The global sodium succinate market is part of the broader modified starch and chemical markets. As of 2023, the market size for sodium succinate was valued at USD 660.49 million, with a projected growth at a Compound Annual Growth Rate (CAGR) of 6.4% until 2030, reaching USD 1019.67 million[2].

Regional Insights

• North America: This region dominates the global sodium succinate market, driven by the high consumption of packaged food and dairy products. Countries like the US, Canada, and Mexico are key players, focusing on developing healthier and more nutritious products[2].
• Asia Pacific: This region is the second largest market, driven by a large population and increasing health awareness. Countries such as China, India, and Japan are significant contributors to the market growth[2].
• Europe: Europe also holds a substantial share of the market, with countries like Germany, France, and the UK being major consumers[5].

End-Use Segmentation

Sodium succinate is used in various applications:

• Food Industry: As an emulsifier, stabilizer, and thickener in food products, particularly in dairy and confectionery items[2].
• Pharmaceuticals: As an intermediate in drug formulations and for its potential therapeutic benefits.
• Cosmetics: In hairdressing products and other cosmetic preparations[2].

Market Projections

Growth Drivers

The market for sodium succinate is driven by several factors:

• Increasing Demand for Functional Foods: Consumers are increasingly opting for healthy and low-calorie diets, driving the demand for functional foods that use sodium succinate as an additive[2].
• Expanding Pharmaceutical Applications: The potential use of sodium succinate in pharmaceutical formulations and its role in energy metabolism could expand its market reach.
• Regulatory Approvals: Favorable regulatory environments in various regions are expected to support market growth[5].

Competitive Landscape

The market is competitive, with several key players involved in the production and supply of sodium succinate. A comprehensive SWOT analysis of these players reveals their market share dynamics, growth strategies, and regional presence[5].

Key Takeaways

• Market Growth: The global sodium succinate market is expected to grow at a CAGR of 6.4% until 2030.
• Regional Dominance: North America leads the market, followed by the Asia Pacific region.
• Diverse Applications: Sodium succinate is used in the food, pharmaceutical, and cosmetic industries.
• Future Potential: There is potential for sodium succinate in future clinical trials and expanded pharmaceutical applications.

FAQs

What is the current market size of the global sodium succinate market?

The global sodium succinate market was valued at USD 660.49 million in 2023[2].

What is the projected growth rate of the sodium succinate market?

The market is expected to grow at a CAGR of 6.4% until 2030[2].

Which region dominates the sodium succinate market?

North America dominates the global sodium succinate market[2].

What are the primary applications of sodium succinate?

Sodium succinate is primarily used as an emulsifier, stabilizer, and thickener in the food industry, and it also has applications in pharmaceuticals and cosmetics[2].

What drives the demand for sodium succinate?

The demand is driven by the increasing need for functional foods, expanding pharmaceutical applications, and favorable regulatory environments[2][5].

Sources

1. Clinical Trials: AALL1821 study - Clinical Trials
2. Global Sodium Octenyl Succinate Starch Market: Maximize Market Research
3. Lasmiditan Succinate Market: Market Research Intellect
4. Xtandi - European Medicines Agency: European Medicines Agency
5. Sodium Succinate Global Market: Research and Markets